CSL Behring To Build High-Speed Syringe Fill Line at its Kankakee (Il) Facility.-- $15 million investment to fill single-dose syringes for seasonal influenza vaccine influenza vaccine Flu vaccine A vaccine recommended for those at high risk for serious complications from influenza: > age 65; Pts with chronic diseases of heart, lung or kidneys, DM, immunosuppression, severe anemia, nursing home and other chronic-care -- KANKAKEE, Ill. -- CSL Behring today announced plans to invest $15 million to expand its manufacturing facility here by adding a high-speed, single-dose syringe filling line. Plans call for the line to be operational in 2010, when the company intends to contract with its sister company, CSL (Computerese as a Second Language) Said of people who love to speak high-tech words even though they often use them erroneously. See TLA. 1. CSL - Computer Structure Language. A computer hardware description language, written in BCPL. Biotherapies, to provide filling and packaging services for seasonal influenza vaccine. CSL Biotherapies anticipates introducing its influenza vaccine to the U.S. beginning with the 2007/08 season. CSL Biotherapies has filed a Biologics License Application (BLA BLA abbr. Bachelor of Liberal Arts ) with the U.S. Food and Drug Administration. The BLA requests that the vaccine be approved to immunize im·mu·nize v. 1. To render immune. 2. To produce immunity in, as by inoculation. im people 18 years of age and older. The approved vaccine will be made available in single-dose, thimerosal-free, pre-filled syringes and in multi-dose vials, providing choice and convenience to caregivers who administer it. CSL Limited, the parent company of both CSL Behring and CSL Biotherapies, previously announced plans to invest $60 million in plant and equipment to double flu manufacturing capacity at its Melbourne, Australia facility. "This additional $15 million investment underscores our continuing commitment to the Kankakee site," said Randy Furby, Senior Vice President and General Manager of the facility. "CSL has made a major, long-term commitment to the U.S. vaccine market, and this building plan represents a key part of our overall business strategy." The Kankakee facility currently employs 600 people. About CSL Behring CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about saving and improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of rare diseases such as immune deficiency disorders, hemophilia, von Willebrand disease Von Willebrand Disease Definition Von Willebrand disease is caused by a deficiency or an abnormality in a protein called von Willebrand factor and is characterized by prolonged bleeding. , other bleeding disorders and inherited emphysema emphysema (ĕmfĭsē`mə), pathological or physiological enlargement or overdistention of the air sacs of the lungs. A major cause of pulmonary insufficiency in chronic cigarette smokers, emphysema is a progressive disease that commonly . Other products are used for the prevention of hemolytic he·mo·lyt·ic adj. Destructive to red blood cells; hematolytic. Hemolytic Referring to the destruction of the cell membranes of red blood cells, resulting in the release of hemoglobin from the damaged cell. diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB ZLB Zero Length Body ZLB Zero Length Bit Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com. About CSL Biotherapies The U.S. headquarters of CSL Biotherapies is located in King of Prussia King of Prussia, industrialized suburban area (1990 pop. 18,406), Montgomery co., SE Pa. It has glass and steel fabricating, food processing, printing and publishing, and varied manufacturing (textiles, liquified petroleum gas, water-treatment and electrical , Pa. Its parent company, CSL Limited, operates one of the world's largest influenza vaccine facilities for global markets in Melbourne, Australia. CSL Biotherapies is commercializing influenza vaccine products globally. At CSL Biotherapies, delivering vaccines is our mission, protecting lives our passion. The CSL Group, which also includes CSL Research & Development, CSL Bioplasma and CSL Behring, has more than 8,500 employees in 21 countries worldwide. For more information, visit us at www.cslbiotherapies-us.com. CSL Behring is a company of CSL Limited. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion